A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure

Completed · Phase 3

Conditions studied: Hypertension

In brief

This is a study for people diagnosed with hypertension to compare 3 doses (75 mg, 150 mg, and 300 mg) of an experimental product, aliskiren in comparison to a placebo. Each patient is in the study for 8 weeks

Key facts

Study ID

NCT00260923

Run by

Novartis

People needed

641

Starts

2005-11-01

Expected to finish

2006-11-01

Last updated by the study team

2011-11-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female outpatients 18 years of age and older
• Patients who are eligible and able to participate in the study

You may not qualify if…

• Severe hypertension
• History or evidence of a secondary form of hypertension
• History of hypertensive encephalopathy or cerebrovascular accident.
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Novartis Pharmaceuticals — East Hanover, New Jersey, United States
• Study site — Investigative Centers, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.